Xencor (NASDAQ:XNCR) Trading 6.3% Higher

Xencor, Inc. (NASDAQ:XNCR) shares were up 6.3% on Monday . The stock traded as high as $21.35 and last traded at $21.24. Approximately 325,761 shares were traded during trading, a decline of 52% from the average daily volume of 679,953 shares. The stock had previously closed at $19.98.

Analyst Ratings Changes

Several analysts recently issued reports on XNCR shares. Wedbush cut their target price on shares of Xencor from $36.00 to $34.00 and set an “outperform” rating for the company in a research report on Wednesday, February 28th. StockNews.com upgraded shares of Xencor from a “sell” rating to a “hold” rating in a research report on Saturday, March 9th. BMO Capital Markets cut their target price on shares of Xencor from $38.00 to $34.00 and set an “outperform” rating for the company in a research report on Wednesday, February 28th. Royal Bank of Canada reiterated an “outperform” rating and issued a $32.00 price target on shares of Xencor in a research report on Wednesday, February 28th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $24.00 price target (down from $37.00) on shares of Xencor in a research report on Wednesday, February 28th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Xencor currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.00.

Xencor Trading Up 5.5 %

The company has a market cap of $1.30 billion, a PE ratio of -10.02 and a beta of 0.76. The stock’s 50 day moving average is $22.02 and its 200-day moving average is $20.36. The company has a quick ratio of 7.36, a current ratio of 7.36 and a debt-to-equity ratio of 0.02.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.67). The business had revenue of $44.70 million for the quarter, compared to analysts’ expectations of $77.63 million. Xencor had a negative net margin of 74.90% and a negative return on equity of 18.67%. Xencor’s revenue for the quarter was up 106.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.20) EPS. As a group, sell-side analysts anticipate that Xencor, Inc. will post -3.25 EPS for the current year.

Insider Activity at Xencor

In other news, Director Kurt A. Gustafson sold 14,000 shares of the stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $23.18, for a total value of $324,520.00. Following the sale, the director now owns 6,007 shares of the company’s stock, valued at $139,242.26. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, VP John R. Desjarlais sold 1,280 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $23.50, for a total value of $30,080.00. Following the transaction, the vice president now owns 186,433 shares of the company’s stock, valued at approximately $4,381,175.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Kurt A. Gustafson sold 14,000 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $23.18, for a total transaction of $324,520.00. Following the completion of the transaction, the director now directly owns 6,007 shares in the company, valued at approximately $139,242.26. The disclosure for this sale can be found here. Insiders have sold a total of 101,351 shares of company stock valued at $2,152,417 over the last 90 days. 4.97% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Parallel Advisors LLC grew its holdings in Xencor by 303.9% during the 4th quarter. Parallel Advisors LLC now owns 1,349 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 1,015 shares in the last quarter. CWM LLC grew its holdings in Xencor by 498.7% during the 4th quarter. CWM LLC now owns 1,377 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 1,147 shares in the last quarter. Signaturefd LLC grew its holdings in Xencor by 367.7% during the 4th quarter. Signaturefd LLC now owns 1,464 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 1,151 shares in the last quarter. BluePath Capital Management LLC bought a new position in Xencor during the 3rd quarter worth about $31,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Xencor by 95.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,548 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 756 shares in the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.